This month's newsletter includes helpful information on:
- New Data & Analytics Reports
- The GPO Vaccine Initiative
- Coding Changes
- Quality Updates
- Important Meeting Dates
This month's newsletter includes helpful information on:
Respiratory syncytial virus (RSV) is a widespread respiratory virus that poses serious health risks for infants and young children. To combat this, the Centers for Disease Control and Prevention (CDC) now recommends RSFP immunization to help prevent severe RSV disease. This can be achieved through maternal vaccination or the administration of the RSV monoclonal antibody (nirsevimab) to infants.
In September 2024, the U.S. Food and Drug Administration (FDA) granted approval for FluMist, the nasal spray influenza vaccine, to be administered by individuals themselves or by caregivers. This new option provides a safe and effective alternative of receiving the seasonal influenza vaccine, offering increased convenience and flexibility for families.